|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Given the differential binding capacity and the favorable radioactivity pattern, (18) F-RB390 represents the portrayal of the first imaging ligand with predictive potential for mutant T877A-AR in prostate cancer for guiding therapy.Prostate 75:348-359, 2015.© 2014 Wiley Periodicals, Inc.
|
25358634 |
2015 |
|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups.
|
25409505 |
2014 |
|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It may be particularly effective against prostate cancer cells with the T878A AR mutation but may also enhance degradation of wild-type AR in vivo through a combination of direct and indirect mechanisms.
|
24874833 |
2014 |
|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of four human prostate cancer cell models were examined: LNCaP (T877A mutant AR), 22Rv1 (H874Y mutant AR), LAPC4 (wild-type AR), and VCaP (wild-type AR).
|
23813737 |
2013 |
|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we demonstrate that genistein, a soy phytoestrogen binds to both the wild and the Thr877Ala (T877A) mutant types of AR competitively with androgen, nevertheless, it exerts a pleiotropic effect on PCa cell proliferation and AR activity depending on the mutational status of the AR.
|
24167630 |
2013 |
|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A prostate cancer mouse model was generated by selectively mutating the AR threonine 877 into alanine in prostatic epithelial cells through Cre-ERT2-mediated targeted somatic mutagenesis.
|
21383160 |
2011 |
|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer.
|
19856921 |
2009 |
|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The androgen-mediated repression of hTERT is abrogated in a human prostate cancer cell line exhibiting hormone-dependent growth, which expresses a mutant AR (T877A) frequently occurring in prostate cancer.
|
17991730 |
2008 |
|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BPA and DHT elicited distinct transcriptional signatures in prostate cancer cells expressing the BPA-responsive mutant AR-T877A.
|
18007998 |
2007 |
|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutation (T877A) of the AR gene found in an androgen-sensitive prostate cancer cell line, LNCaP, has been postulated to be involved in hypersensitivity and loss of specificity for androgen.
|
17312014 |
2007 |
|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Taken together, these findings provide novel insights into the AR dysfunctions resulting from the T877A mutation and functionally similar AR alterations may provide selective cell growth/survival advantage for CaP progression.
|
16636679 |
2006 |
|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The T877A mutant of the AR frequently found in advanced cases of prostate cancer displays an exaggerated stimulation of transcriptional activity by CDK6.
|
15790678 |
2005 |
|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The cortisol/cortisone-responsive AR (AR(ccr)) has two mutations (L701H and T877A) that were found in the MDA PCa human prostate cancer cell lines established from a castrated patient whose metastatic tumor exhibited androgen-independent growth.
|
11956172 |
2002 |
|
rs137852578
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al.Nature Med.2000, 6, 703-6).
|
11906285 |
2002 |
|
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk.
|
21177315 |
2011 |
|
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk.
|
21177315 |
2011 |
|
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
|
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
|
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
|
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
|
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Conversely, no association was observed between prostate carcinoma risk and the other polymorphisms studied as follow: the CAG repeat in exon 1 of AR, the (TA)n dinucleotide repeat polymorphism in the 3' untranslated region, and the A49T or V89L substitutions in SDR5A2, the single base pair (bp) (a T to C transition) polymorphism that creates an additional Sp1-type (CCACC box) promoter site in CYP17.
|
11571725 |
2001 |
|
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Conversely, no association was observed between prostate carcinoma risk and the other polymorphisms studied as follow: the CAG repeat in exon 1 of AR, the (TA)n dinucleotide repeat polymorphism in the 3' untranslated region, and the A49T or V89L substitutions in SDR5A2, the single base pair (bp) (a T to C transition) polymorphism that creates an additional Sp1-type (CCACC box) promoter site in CYP17.
|
11571725 |
2001 |
|
rs137852593
|
|
|
0.040 |
GeneticVariation |
BEFREE |
R726L substitution in the hormone binding region of androgen receptor was found in 1 prostate cancer family but no previously uncharacterized germline mutations were detected.
|
14665948 |
2004 |